Worldwide Healthcare Trust Regulatory News (WWH)

London, UK, 12 January 2023

Worldwide Healthcare Trust (WWH): Sticking to the successful long-term strategy

Worldwide Healthcare Trust's two co-managers, Sven Borho and Trevor Polischuk at specialist investor OrbiMed, remain positive on the prospects for the global healthcare industry. This view is based on favourable company fundamentals, increased clarity on US drug pricing and an upturn in merger and acquisition activity, as pharma companies are using their strong balance sheets to bolster their product pipelines. The trust's portfolio remains skewed to emerging (smaller-cap) biotech and emerging market stocks rather than large-cap pharma companies. While this strategy has been detrimental to WWH's relative performance in recent quarters, this active approach has been successful over the longer term.

WWH's 6.1% share price discount to cum-income NAV compares with a 1.2% premium to a 10.6% discount over the last 12 months. It compares with the average discounts of 6.6%, 2.0%, 1.0% and 2.4% over the last one, three, five and 10 years, respectively. If the trust's relative performance improves, there is potential for a higher valuation; prior to Q121 WWH's shares regularly traded close to NAV.

Click here to view the full report or here to sign up to receive research as it is published.

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner +44 (0)20 3681 2500 investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn www.linkedin.com/company/edison-group-/

Twitter www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv